目的 探討婦科止帶膠囊聯(lián)合甲硝唑片治療慢性盆腔炎的臨床療效。方法 選取2015年3月—2016年7月遼陽市中心醫(yī)院接收的慢性盆腔炎患者120例為研究對象，所有患者隨機(jī)分為對照組和治療組，每組各60例。對照組口服甲硝唑片，0.4 g/次，2次/d。治療組在對照組基礎(chǔ)上口服婦科止帶膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組的血清細(xì)胞因子水平和臨床癥狀評分。結(jié)果 治療后，對照組和治療組的總有效率分別為81.67%、93.33%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組白細(xì)胞介素-4（IL-4）水平明顯升高，腫瘤壞死因子-α（TNF-α）、超敏反應(yīng)C蛋白（hs-CRP）水平明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組臨床癥狀評分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組臨床癥狀評分明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 婦科止帶膠囊聯(lián)合甲硝唑片治療慢性盆腔炎具有較好的臨床療效，能改善臨床癥狀，調(diào)節(jié)血清細(xì)胞因子水平，安全性較好，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Fukezhidai Capsules combined with Metronidazole Tablets in treatment of chronic pelvic inflammatory disease. Methods Women (120 cases) with chronic pelvic inflammatory disease in Liaoyang City Central Hospital from March 2015 to July 2016 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Metronidazole Tablets, 0.4 g/time, twice daily. Patients in the treatment group were po administered with Fuke Zhidai Capsules on the basis of the control group, 4 capsules/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the clinical symptom scores and inflammatory factor levels before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 93.33%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of IL-4 in two groups were significantly increased, but the levels of TNF-α and hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, clinical symptom scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And clinical symptom scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Fukezhidai Capsules combined with Metronidazole Tablets has clinical curative effect in treatment of chronic pelvic inflammatory disease, can improve the clinical symptoms and regulate the level of serum cytokine with better safety, which has a certain clinical application value.